Investigation of the Off-Label Drug Use at Provincial and Regional Levels

被引:4
|
作者
Bayram, Dilara [1 ]
Kirmizi, N. Ipek [1 ]
Ozdamar, Emine Nur [2 ]
Bayar, Banu [3 ]
Gursoz, Hakki [3 ]
Akici, Ahmet [1 ]
机构
[1] Marmara Univ, Tip Fak, Tibbi Farmakoloji Ana Bilim Dali, Istanbul, Turkey
[2] Saglik Bakanligi Konya Meram Egitim & Arastirma H, Konya, Turkey
[3] Turkiye Ilac & Tibbi Cihaz Kurumu, Saglik Bakanligi, Ankara, Turkey
来源
GAZI MEDICAL JOURNAL | 2018年 / 29卷 / 04期
关键词
Off label drug use; regional differences; NUTS-1; cities;
D O I
10.12996/gmj.2018.85
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The use of drugs outside the purpose for which they are approved, e.g. different indications, doses, administration forms, age groups, or special populations etc. is called "off-label drug use" (OLDU). This study aimed to investigate OLDU at provincial and territorial levels in Turkey. Methods: A total of 5681 applications submitted to the Turkish Medicines and Medical Devices Agency in 2011 were investigated. These applications were examined at provincial and NUTS-1 (Nomenclature of Territorial Units for Statistics-1) levels based on age, sex, time and place of application, etc. and top five most common drugs for each region. Results: OLDU applications were submitted mainly during Quarter 2 and 81.6% of them were from university hospitals. Except for "Southeastern Anatolia", the average age was >30-year in all regions and majority of patients (55.1%) were female. Applications were mostly submitted from "Western Anatolia" (34.9%), followed by "Istanbul" (26,5%) and "Aegean" (10,3%) regions at institutional level. The highest and lowest number of applications per 1000 specialist physician at provincial level were Cankiri (778.8) and Istanbul (20.0), respectively. While varying by rank among NUTS-1 regions, most commonly applied drugs were rituximab, mycophenolate mofetil, and iloprost trometamol. Conclusion: Rational OLDU practice depends on some critical factors including regional characteristics. This study is the first to show variations of OLDU applications at provincial and regional level, which need to be considered to improve functionality of OLDU. These findings are expected to shed light on new regulations and studies that will elucidate the causes of differences.
引用
收藏
页码:312 / 318
页数:7
相关论文
共 50 条
  • [1] Investigation of off-label drug use in pediatric patients
    Akici, N.
    Kirmizi, N. I.
    Aydin, V.
    Bayar, B.
    Akici, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S55 - S55
  • [2] Appropriate off-label drug use
    Lee, Sang Moo
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2018, 61 (03): : 140 - 146
  • [3] Off-Label Drug Use and Promotion
    Gianutsos, Gerald
    [J]. US PHARMACIST, 2014, 39 (10) : 55 - 64
  • [4] Off-label drug use in children
    Jain S.S.
    Bavdekar S.B.
    Gogtay N.J.
    Sadawarte P.A.
    [J]. The Indian Journal of Pediatrics, 2008, 75 (11) : 1133 - 1136
  • [5] Off-Label Drug Use in Children
    Jain, Surabhi S.
    Bavdekar, S. B.
    Gogtay, Nithya J.
    Sadawarte, Pranjali A.
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2008, 75 (11): : 1133 - 1136
  • [6] Off-label drug use in hospitals
    Danes, Imma
    Alerany, Carmen
    Ferrer, Anna
    Vallano, Antoni
    [J]. MEDICINA CLINICA, 2014, 143 (07): : 327 - 328
  • [7] An Investigation of the Off-Label Use of Bevacizumab
    Liu, Tao
    Chen, Zhuo-Jia
    Lin, Zi-Chao
    Chen, Fu-Qin
    Huang, Hong-Bing
    [J]. LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (03): : 480 - 487
  • [8] Off-label Drug Use and Adverse Drug Events Turning up the Heat on Off-label Prescribing
    Good, Chester B.
    Gellad, Walid F.
    [J]. JAMA INTERNAL MEDICINE, 2016, 176 (01) : 63 - 64
  • [9] OFF-LABEL DRUG USE IN CHILDHOOD ASTHMA
    Kling, Sharon
    [J]. CURRENT ALLERGY & CLINICAL IMMUNOLOGY, 2011, 24 (01) : 38 - 41
  • [10] Off-Label Drug Use: The Bevacizumab Story
    Stewart, Michael W.
    [J]. MAYO CLINIC PROCEEDINGS, 2013, 88 (03) : 305 - 305